These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 17251563)

  • 21. Sequence and functional analysis of the envelope glycoproteins of hepatitis C virus variants selectively transmitted to a new host.
    D'Arienzo V; Moreau A; D'Alteroche L; Gissot V; Blanchard E; Gaudy-Graffin C; Roch E; Dubois F; Giraudeau B; Plantier JC; Goudeau A; Roingeard P; Brand D
    J Virol; 2013 Dec; 87(24):13609-18. PubMed ID: 24109215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatitis C virus (HCV) genotype distribution in German isolates: studies on the sequence variability in the E2 and NS5 region.
    Driesel G; Wirth D; Stark K; Baumgarten R; Sucker U; Schreier E
    Arch Virol; 1994; 139(3-4):379-88. PubMed ID: 7832643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies Targeting Novel Neutralizing Epitopes of Hepatitis C Virus Glycoprotein Preclude Genotype 2 Virus Infection.
    Deng K; Liu R; Rao H; Jiang D; Wang J; Xie X; Wei L
    PLoS One; 2015; 10(9):e0138756. PubMed ID: 26406225
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Sequence diversity and variability in the putative envelope proteins including hypervariable regions of hepatitis C virus].
    Nakazawa T; Hijikata M; Kato N; Shimotohno K
    Nihon Rinsho; 1993 Feb; 51(2):318-22. PubMed ID: 8385235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Full-length characterization of hepatitis C virus subtype 3a reveals novel hypervariable regions under positive selection during acute infection.
    Humphreys I; Fleming V; Fabris P; Parker J; Schulenberg B; Brown A; Demetriou C; Gaudieri S; Pfafferott K; Lucas M; Collier J; Huang KH; Pybus OG; Klenerman P; Barnes E
    J Virol; 2009 Nov; 83(22):11456-66. PubMed ID: 19740991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of hypervariable regions in the putative envelope protein of hepatitis C virus.
    Kato N; Ootsuyama Y; Ohkoshi S; Nakazawa T; Sekiya H; Hijikata M; Shimotohno K
    Biochem Biophys Res Commun; 1992 Nov; 189(1):119-27. PubMed ID: 1333186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Sequence diversity of genotype II/1b hepatitis C virus (HCV) HVR1 of 46 patients in Beijing areas].
    Zhao J; Cheng Y; Zhang H
    Zhonghua Gan Zang Bing Za Zhi; 1999 Jun; 7(2):88-90. PubMed ID: 10488415
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of a hepatitis C virus genotype 1 divergent isolate from an HIV-1 coinfected individual in Germany assigned to a new subtype 1o.
    Wang B; Krüger L; Machnowska P; Eshetu A; Gunsenheimer-Bartmeyer B; Bremer V; Hauser A; Bannert N; Bock CT
    Virol J; 2019 Mar; 16(1):28. PubMed ID: 30832687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.
    Li H; McMahon BJ; McArdle S; Bruden D; Sullivan DG; Shelton D; Deubner H; Gretch DR
    Virology; 2008 Jun; 375(2):580-91. PubMed ID: 18343477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substitution of the CD81 Binding Site and β-Sandwich Area in E2 of HCV in Cambodia.
    Yamamoto C; Nagashima S; Chuon C; Ko K; Huy Do S; Lim O; Hok S; Svay S; Matsuo J; Katayama K; Takahashi K; Tanaka J
    Viruses; 2020 May; 12(5):. PubMed ID: 32429467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatitis C Virus Escape Studies of Human Antibody AR3A Reveal a High Barrier to Resistance and Novel Insights on Viral Antibody Evasion Mechanisms.
    Velázquez-Moctezuma R; Galli A; Law M; Bukh J; Prentoe J
    J Virol; 2019 Feb; 93(4):. PubMed ID: 30487284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genotype distribution and comparison of the putative envelope region of hepatitis C virus from Korean patients.
    Kim CJ; Shin KS; Kim WY; Lim DS; Yoon SK; Park YM; Kim BS; Jang SK; Cho MJ
    J Med Virol; 1995 Aug; 46(4):380-6. PubMed ID: 7595417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
    Khera T; Behrendt P; Bankwitz D; Brown RJP; Todt D; Doepke M; Khan AG; Schulze K; Law J; Logan M; Hockman D; Wong JAJ; Dold L; Gonzalez-Motos V; Spengler U; Viejo-Borbolla A; Ströh LJ; Krey T; Tarr AW; Steinmann E; Manns MP; Klein F; Guzman CA; Marcotrigiano J; Houghton M; Pietschmann T
    J Hepatol; 2019 Apr; 70(4):593-602. PubMed ID: 30439392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of new functional regions in hepatitis C virus envelope glycoprotein E2.
    Albecka A; Montserret R; Krey T; Tarr AW; Diesis E; Ball JK; Descamps V; Duverlie G; Rey F; Penin F; Dubuisson J
    J Virol; 2011 Feb; 85(4):1777-92. PubMed ID: 21147916
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Variations in the hypervariable region 1 of the envelope region E2 of hepatitis C virus RNA appear associated with virus persistence independently of liver disease.
    Brunetto MR; Suzuki T; Aizaky H; Flichman D; Colombatto P; Abate ML; Oliveri F; Matsuura Y; Bonino F; Miyamura T
    Ital J Gastroenterol; 1996 Dec; 28(9):499-504. PubMed ID: 9131394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Experimental vaccine activities of recombinant E1 and E2 glycoproteins and hypervariable region 1 peptides of hepatitis C virus in chimpanzees.
    Esumi M; Rikihisa T; Nishimura S; Goto J; Mizuno K; Zhou YH; Shikata T
    Arch Virol; 1999; 144(5):973-80. PubMed ID: 10416378
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Study of a novel hypervariable region in hepatitis C virus (HCV) E2 envelope glycoprotein.
    Troesch M; Meunier I; Lapierre P; Lapointe N; Alvarez F; Boucher M; Soudeyns H
    Virology; 2006 Sep; 352(2):357-67. PubMed ID: 16781757
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Iatrogenic transmission of hepatitis C virus (HCV) by an anesthesiologist: comparative molecular analysis of the HCV-E1 and HCV-E2 hypervariable regions.
    Shemer-Avni Y; Cohen M; Keren-Naus A; Sikuler E; Hanuka N; Yaari A; Hayam E; Bachmatov L; Zemel R; Tur-Kaspa R
    Clin Infect Dis; 2007 Aug; 45(4):e32-8. PubMed ID: 17638183
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C.
    Pawlotsky JM; Pellerin M; Bouvier M; Roudot-Thoraval F; Germanidis G; Bastie A; Darthuy F; Rémiré J; Soussy CJ; Dhumeaux D
    J Med Virol; 1998 Apr; 54(4):256-64. PubMed ID: 9557291
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification, molecular cloning, and analysis of full-length hepatitis C virus transmitted/founder genotypes 1, 3, and 4.
    Stoddard MB; Li H; Wang S; Saeed M; Andrus L; Ding W; Jiang X; Learn GH; von Schaewen M; Wen J; Goepfert PA; Hahn BH; Ploss A; Rice CM; Shaw GM
    mBio; 2015 Feb; 6(2):e02518. PubMed ID: 25714714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.